Tags

Type your tag names separated by a space and hit enter

[Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
Ital Heart J Suppl. 2004 Jun; 5(6):436-44.IH

Abstract

Cardiovascular disease is the major cause of morbidity and mortality in patients with chronic kidney disease (CKD). The presence of CKD whether manifested by albuminuria or reduction in glomerular filtration rate is an independent risk factor for cardiovascular outcome. This is mainly due to both an overexpression of traditional cardiovascular risk factors, and the onset of new factors which are peculiar of CKD. In this revision the role of arterial hypertension and of dyslipidemia is analyzed in detail. Most interventional trials have demonstrated that a reduction of blood pressure and the normalization of lipid profile are associated with a significant reduction in the incidence of major cardiovascular events and mortality. According to the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) recommendations, patients with CKD, regardless of the stage of disease, should be considered the highest risk group for cardiovascular events. For these patients the NKF-K/DOQI guidelines recommend strict blood pressure control, renin-angiotensin system blockade, and the use of statins with target LDL cholesterol levels < 100 mg/dl.

Authors+Show Affiliations

Ravera M
Clinica Nefrologica, Dipartimento di Medicina Interna, Università degli Studi, Genova. mauraravera@libero.it
Paoletti E
No affiliation info available

MeSH

AgedAlbuminuriaCardiovascular DiseasesCholesterol, LDLChronic DiseaseClinical Trials as TopicCohort StudiesFemaleFollow-Up StudiesGlomerular Filtration RateHumansHyperlipidemiasHypertensionHypolipidemic AgentsKidney DiseasesKidney Failure, ChronicKidney TransplantationMalePractice Guidelines as TopicPrevalenceRenal DialysisRenin-Angiotensin SystemRisk FactorsTime Factors

Pub Type(s)

Comparative Study
English Abstract
Journal Article
Review

Language

ita

PubMed ID

15471148

Citation

Ravera, Maura, and Ernesto Paoletti. "[Hypertension, Dyslipidemia and Cardiovascular Risk in Chronic Renal Disease]." Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology, vol. 5, no. 6, 2004, pp. 436-44.
Ravera M, Paoletti E. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease]. Ital Heart J Suppl. 2004;5(6):436-44.
Ravera, M., & Paoletti, E. (2004). [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease]. Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology, 5(6), 436-44.
Ravera M, Paoletti E. [Hypertension, Dyslipidemia and Cardiovascular Risk in Chronic Renal Disease]. Ital Heart J Suppl. 2004;5(6):436-44. PubMed PMID: 15471148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease]. AU - Ravera,Maura, AU - Paoletti,Ernesto, PY - 2004/10/9/pubmed PY - 2004/10/29/medline PY - 2004/10/9/entrez SP - 436 EP - 44 JF - Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology JO - Ital Heart J Suppl VL - 5 IS - 6 N2 - Cardiovascular disease is the major cause of morbidity and mortality in patients with chronic kidney disease (CKD). The presence of CKD whether manifested by albuminuria or reduction in glomerular filtration rate is an independent risk factor for cardiovascular outcome. This is mainly due to both an overexpression of traditional cardiovascular risk factors, and the onset of new factors which are peculiar of CKD. In this revision the role of arterial hypertension and of dyslipidemia is analyzed in detail. Most interventional trials have demonstrated that a reduction of blood pressure and the normalization of lipid profile are associated with a significant reduction in the incidence of major cardiovascular events and mortality. According to the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) recommendations, patients with CKD, regardless of the stage of disease, should be considered the highest risk group for cardiovascular events. For these patients the NKF-K/DOQI guidelines recommend strict blood pressure control, renin-angiotensin system blockade, and the use of statins with target LDL cholesterol levels < 100 mg/dl. SN - 1129-4728 UR - https://www.unboundmedicine.com/medline/citation/15471148/[Hypertension_dyslipidemia_and_cardiovascular_risk_in_chronic_renal_disease]_ DB - PRIME DP - Unbound Medicine ER -